Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes
Nature medicine, 2020•nature.com
Improving early cancer detection has the potential to substantially reduce cancer-related
mortality. Cell-free methylated DNA immunoprecipitation and high-throughput sequencing
(cfMeDIP–seq) is a highly sensitive assay capable of detecting early-stage tumors. We
report accurate classification of patients across all stages of renal cell carcinoma (RCC) in
plasma (area under the receiver operating characteristic (AUROC) curve of 0.99) and
demonstrate the validity of this assay to identify patients with RCC using urine cell-free DNA …
mortality. Cell-free methylated DNA immunoprecipitation and high-throughput sequencing
(cfMeDIP–seq) is a highly sensitive assay capable of detecting early-stage tumors. We
report accurate classification of patients across all stages of renal cell carcinoma (RCC) in
plasma (area under the receiver operating characteristic (AUROC) curve of 0.99) and
demonstrate the validity of this assay to identify patients with RCC using urine cell-free DNA …
Abstract
Improving early cancer detection has the potential to substantially reduce cancer-related mortality. Cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP–seq) is a highly sensitive assay capable of detecting early-stage tumors. We report accurate classification of patients across all stages of renal cell carcinoma (RCC) in plasma (area under the receiver operating characteristic (AUROC) curve of 0.99) and demonstrate the validity of this assay to identify patients with RCC using urine cell-free DNA (cfDNA; AUROC of 0.86).
nature.com
